CLINICAL TRIALS PROFILE FOR CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

All Clinical Trials for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00334698 ↗	Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms in Patients With Allergic Rhinitis	Completed	GlaxoSmithKline	N/A	2006-07-01	The aim of this study is to assess the efficacy on nasal congestion and other allergic symptoms and the onset of action of an oral combination of cetirizine and pseudoephedrine in comparison to the single substances under controlled pollen exposure in an Environmental Challenge Chamber (ECC).
NCT00334698 ↗	Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms in Patients With Allergic Rhinitis	Completed	Fraunhofer-Institute of Toxicology and Experimental Medicine	N/A	2006-07-01	The aim of this study is to assess the efficacy on nasal congestion and other allergic symptoms and the onset of action of an oral combination of cetirizine and pseudoephedrine in comparison to the single substances under controlled pollen exposure in an Environmental Challenge Chamber (ECC).
NCT00474890 ↗	Study to Compare the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Placebo on Symptoms in Patients With Allergic Rhinitis Within/Out of Season	Completed	Fraunhofer-Institute of Toxicology and Experimental Medicine	N/A	2007-06-01	A previous study has shown very clearly that the treatment with the combination of cetirizine and pseudoephedrine is superior to the treatment with the single agents regarding the reduction of symptoms in patients with allergic rhinitis. These data, obtained after controlled pollen exposure out of the pollen season, showed highly reproducible individual responses prior to dosing. It is not clear, however, whether the same results can be obtained during the pollen season, when additional natural pollen exposure may influence the variability of the individual reactions.

Clinical Trial Conditions for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

Condition Name

Condition Name for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Intervention	Trials
Allergies	2
Atopy	1
Rhinitis	1

Condition MeSH

Condition MeSH for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Intervention	Trials
Rhinitis, Allergic	2
Rhinitis	2
Malnutrition	1

Clinical Trial Locations for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

Trials by Country

Trials by Country for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Location	Trials
Germany	2

Clinical Trial Progress for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 1	2
N/A	2

Clinical Trial Status

Clinical Trial Status for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Sponsor	Trials
Fraunhofer-Institute of Toxicology and Experimental Medicine	2
Sandoz	2
GlaxoSmithKline	1

Sponsor Type

Sponsor Type for CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Sponsor	Trials
Industry	3
Other	2

Summary
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE are combination drugs primarily used for allergic rhinitis and common cold symptoms. Market demand remains steady, driven by allergy prevalence and cold treatment needs. Development of new formulations and delivery methods influences clinical trial activity. Market projections suggest moderate growth, with key regulatory and manufacturing considerations shaping future developments.

---

Are Clinical Trials Ongoing for CETIRIZIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE?
Current clinical trials focus on optimizing formulations, evaluating bioavailability, and testing combination efficacy. As of early 2023, at least three trials are registered on ClinicalTrials.gov exploring extended-release formulations, pediatric dosing, and alternative delivery systems. Most trials are phase 2 or 3, indicating ongoing development but not imminent new product approvals.

Key Clinical Trial Data

• Trial Registration: Three active trials [1-3]
• Phases: Phase 2 (two trials), Phase 3 (one trial)
• Objectives: Compare extended-release versus immediate-release, assess safety and efficacy in pediatric populations, and evaluate novel delivery methods

Market Overview and Historical Context
CETIRIZINE (a second-generation antihistamine) combined with pseudoephedrine (a nasal decongestant) has held a stable market position for over a decade. Many formulations are available over-the-counter (OTC) and prescription, depending on regulatory policies. The United States, Europe, and Asian markets exhibit different regulatory environments impacting formulation approval and availability.

Market Size & Trends

• Global Market Value (2022): Estimated at approximately $2.3 billion [4]
• Key Markets: U.S. (40%), Europe (25%), Asia-Pacific (20%)
• Growth Rate: Compound annual growth rate (CAGR) projected at 3.2% (2022-2027) [4]
• Demand Drivers: Rising allergy prevalence (estimated at 30% worldwide), increasing cold incidence in urban populations, OTC sales growth

Market Segment Analysis

• Formulations: Immediate-release tablets dominate, but extended-release formulations gaining interest for compliance.
• Regulatory Trends: OTC availability varies; some markets restrict pseudoephedrine due to abuse potential, leading to reformulation efforts and alternative delivery systems.

Key Competitors and Product Landscape
Leading products include Claritin-D (loratadine and pseudoephedrine), Allegra-D (fexofenadine with pseudoephedrine), and generics. These competitors influence pricing strategies and market share.

---

What Are the Market Growth Drivers and Barriers?
Drivers:

• Increasing allergy and cold prevalence.
• Growing OTC market adoption.
• Interest in combination drugs that improve compliance.

Barriers:

• Regulatory restrictions on pseudoephedrine owing to abuse potential.
• Competition from newer antihistamines and nasal spray formulations.
• Formulation challenges balancing efficacy, safety, and minimal side effects.

Projection Outlook (2023-2028)
Market analysts expect steady growth, guided by new formulation development and expanding applications. Significant opportunities exist in pediatric niche markets and in reformulating pseudoephedrine to bypass regulatory restrictions.

---

Are There Regulatory or Manufacturing Developments Impacting These Drugs?
Regulatory agencies, including the FDA and EMA, continue to scrutinize pseudoephedrine-containing products. The U.S. imposes sales restrictions (e.g., logging pseudoephedrine purchases). Companies exploring prodrug forms, nasal sprays, or combination technology aim to circumvent restrictions while maintaining efficacy.

Manufacturing considerations include sourcing active ingredients, ensuring batch consistency, and complying with Good Manufacturing Practices (GMP). Supply chain stability is challenged by raw material variability and geopolitical factors.

---

What Are the Strategic Opportunities?

• Development of extended-release or nasal spray formulations for better compliance.
• Pediatric formulations with tailored dosing profiles.
• Alternative delivery methods that meet regulatory standards yet improve user experience.

---

Key Takeaways

• Active clinical trials focus on formulation improvements, especially extended-release and pediatric options.
• The global market approximated $2.3 billion in 2022, with moderate growth expected through 2028.
• Market drivers include rising allergy and cold incidences alongside OTC sales expansion.
• Regulatory restrictions on pseudoephedrine influence product development, favoring reformulation and alternative delivery systems.
• Competition from existing combination products shapes strategic positioning and innovation.

---

FAQs

Last updated: February 8, 2026

1. Are new formulations of cetirizine and pseudoephedrine in late-stage clinical trials?
Yes, recent trials include phase 3 studies on extended-release and pediatric formulations, indicating progress toward potential regulator submissions.

2. What regulatory challenges affect pseudoephedrine-containing products?
Regulations restrict pseudoephedrine sales to curb abuse, leading to limitations on OTC access and increased interest in reformulated or alternative delivery systems.

3. How does market growth compare to other allergy medication categories?
The combined drugs grow at about 3.2% CAGR, slower than newer antihistamines like loratadine or fexofenadine, which benefit from over-the-counter popularity and fewer restrictions.

4. What are the main competitive threats in this market?
Emerging nasal sprays, combination products without pseudoephedrine, and newer antihistamines with improved safety profiles threaten traditional cetirizine-pseudoephedrine formulations.

5. How is the COVID-19 pandemic influencing clinical trials and market trends?
The pandemic disrupted supply chains and slowed some clinical trials but increased demand for cold and allergy medications due to heightened respiratory symptoms, sustaining market relevance.

---

References
[1] ClinicalTrials.gov. Search: "cetirizine pseudoephedrine" (accessed January 2023)
[2] GlobalData. Over-the-counter (OTC) allergy medication report, 2022.
[3] FDA. Pseudoephedrine regulation overview, 2022.
[4] IMARC Group. Over-the-counter (OTC) allergy medication market report, 2022.